The Pharma Data

DECEMBER 2, 2020

This License Agreement represents an important corporate milestone. This License Agreement represents an important corporate milestone. The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform.

Licensing 52

Licensing Licensing Vaccine Virus 52

The Pharma Data

JANUARY 20, 2021

a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its company highlights for 2020 which have exceeded revenue targets. . DOYLESTOWN, Pa. , OrthogenRx Inc.

Production 52

Production Treatment Compliance Licensing 52

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). In 2020 global sales of ACTEMRA ® were 2.8 Biogen Inc. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. billion CHF.

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

The Pharma Data

NOVEMBER 26, 2020

27, 2020 /PRNewswire/ — BioInvent International AB ‘s (publ) (“BioInvent”) (OMXS: BINV) Extraordinary General Meeting (the “EGM”) today resolved to approve the Board of Directors’ resolution on a directed issue of 29,395,311 new shares and 14,697,655 new warrants to CASI Pharmaceuticals Inc.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

JANUARY 5, 2021

Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged. To accommodate the delay caused by these unforeseen circumstances, Targovax has granted to IOVaxis an extension to the license option period by 3 months.

Licensing 40

Licensing Licensing Vaccine Clinical Development 40

Drug Channels

OCTOBER 13, 2020

I am pleased to announce our new 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Drug Distribution Industry (press release) We’re offering special discounted pricing if you order before October 23, 2020! Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmaceuticals 52

Pharmaceuticals Licensing Licensing Pharmacy 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ – Crescita Therapeutics Inc. Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). . LAVAL, QC, Nov.

Licensing 40

Licensing Licensing Production Engineering 40

The Pharma Data

DECEMBER 20, 2020

” Under the License Agreement, Peijia and HighLife will establish a joint review committee to enhance a mutual sharing of information about the development as well as commercialization of the TMVR products, further deepening cooperation between the two companies. SUZHOU, China and PARIS , Dec. SUZHOU, China and PARIS , Dec.

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

MAY 7, 2021

under an Emergency Use Authorization (EUA) granted by the FDA on December 11, 2020. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 10:45 UTC. –( BUSINESS WIRE )– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2020. 2020. for the third quarter of 2020. . for the third quarter of 2020. KENILWORTH, N.J.–(

Vaccine 40

Vaccine Trials Treatment Production 40

The Pharma Data

NOVEMBER 19, 2020

20, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2020. GUANGZHOU, China, Nov.

Hospitals 52

Hospitals Laboratories Marketing Research 52

The Pharma Data

DECEMBER 21, 2020

The FDA granted cilta-cel Breakthrough Therapy and Orphan Drug designations in 2019, and the therapy received a PRIME Priority Medicines designation from the European Commission (EC) that same year and an Orphan Drug designation from the EC in February 2020. Cilta-cel also won a Breakthrough Therapy designation in China in August.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

The Pharma Data

JANUARY 21, 2021

These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 3, 2020

The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. million investment announced in July.

Vaccine 52

Vaccine Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 11:00 UTC. NASDAQ: CNCE) today reported financial results for the third quarter of 2020. Our team has diligently and effectively executed on our plan, and I’m pleased that we have achieved our stated 2020 pipeline milestones. Initiated CTP-543 THRIVE-AA1 Phase 3 Trial in November 2020. LEXINGTON, Mass.–(

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 5, 2020

05, 2020 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2020 and provided a corporate update. “In million in the 2020 Quarter, compared to $46.5

Production 52

Production Pharmaceuticals Marketing Pharmaceutical Companies 52

The Pharma Data

AUGUST 17, 2020

Food and Drug Administration clearance in May 2020 for its investigational new drug application to develop DF6002. In addition, Dragonfly has an ongoing Phase 1/2 clinical trial for patients with advanced solid tumors, which began in July 2020. Dragonfly received U.S.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

5, 2020 /PRNewswire/ — Third quarter 2020 revenues increased 32% to $2.29 Third quarter 2020 EYLEA ® U.S. Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07

Production 52

Production FDA Trials FDA Approval 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — OBI Pharma, Inc. “Based upon our anti-Globo H targeted approaches in cancers of high unmet needs, OBI Pharma is proud to have presentations on the progress of our trial presented at ESMO-Asia 2020 for our novel therapeutic cancer vaccine, OBI-833.” TAIPEI, Taiwan , Nov. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

MAY 6, 2021

This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended September 30, 2020. ” THIRD QUARTER 2020 FINANCIAL RESULTS. .” ” THIRD QUARTER 2020 FINANCIAL RESULTS. 2020. 2020.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — Q4 2020 highlights. Entered an exclusive license and supply agreement with Accord Healthcare for ZUBSOLV® covering 29 European countries. 2020. 2020. 2019-2020. 2020.

Therapies 52

Therapies Production Treatment FDA 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET. AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

JANUARY 9, 2021

Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020. NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.

Government 52

Government Vaccine Production Licensing 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

NOVEMBER 11, 2020

12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. Piper Sandler 32nd Annual Healthcare Conference, November 30 – December 3, 2020. Third Quarter 2020 Financial Results. million as of September 30, 2020. million for the third quarter ended September 30, 2020, compared to $3.3

Clinical Trials 40

Clinical Trials Trials Disease FDA 40

The Pharma Data

NOVEMBER 4, 2020

Total Revenue Increased 39% in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared toSame Periods of 2019 Despite COVID-19 Headwinds. Key A chievements in Third Quarter 2020 (and recent weeks). Court of Appeals for the Federal Circuit upheld the March 2020 U.S.

Production 40

Production FDA Trials Disease 40

The Pharma Data

DECEMBER 13, 2020

14, 2020 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. . Relay Therapeutics to host conference call at 8:00 a.m. CAMBRIDGE, Mass., In addition, any forward-looking statements represent Relay Therapeutics’ views only as of today and should not be relied upon as representing its views as of any subsequent date.

Licensing 40

Licensing Licensing Clinical Trials Small Molecule 40

The Pharma Data

DECEMBER 1, 2020

2, 2020 04:00 UTC. The offering is expected to close on December 4, 2020, subject to customary closing conditions. We also market or plan to market in China additional oncology products licensed from Amgen Inc., CAMBRIDGE, Mass. & & BEIJING–( BUSINESS WIRE )– BeiGene, Ltd. Goldman Sachs & Co.

Licensing 40

Licensing Licensing Production Marketing 40

The Pharma Data

OCTOBER 15, 2020

Takeda Pharmaceutical announced this month that it has linked up with Arrowhead Pharmaceuticals to develop and license ARO-AAT, a phase 2 investigational therapy for treating liver disease associated with AATD. That trial is continuing to enroll and dose patients, and results are expected in the first half of 2021. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

FDA cited February 16, 2021, as the first date on which another manufacturer could have marketed its NMN-containing dietary supplement lawfully after submitting an NDIN to the Agency on December 3, 2020. FDA did not disclose the exact date of the IND because that information is confidential.

Production 59

Production FDA Licensing Licensing 59

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Bactiguard presents updated financial targets for 2025 in connection with the company’s financial report for the third quarter of 2020. We have several interesting licensing projects ongoing and see new, exciting business opportunities. STOCKHOLM , Nov. unchanged).

Licensing 52

Licensing Licensing Production Marketing 52

The Pharma Data

DECEMBER 14, 2020

14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. The offering is expected to close on December 17, 2020, subject to the satisfaction of customary closing conditions. NEW YORK, Dec. The offering was upsized from the previously announced offering size of approximately $200,000,000 of common stock.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40

The Pharma Data

DECEMBER 21, 2020

21, 2020 — Long-term care workers in nursing homes commonly hold multiple jobs, which may be contributing to the spread of COVID-19 in nursing homes, according to a study published online Nov. percent of licensed practical nurses and registered nurses held second jobs. © 2020 HealthDay. Posted: December 2020.

Nurses 52

Nurses Licensing Licensing Research 52

The Pharma Data

DECEMBER 16, 2020

17, 2020 09:00 UTC. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., VICTORIA, British Columbia & ROCKVILLE, Md.–( –( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52